Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study

TROPION-Breast01 met its dual primary endpoint of PFS by BICR. While there was no statistically significant improvement in the dual primary endpoint of OS with Dato-DXd versus ICC, subsequent ADC treatment may have affected OS results. The totality of efficacy and safety data supports Dato-DXd as a new treatment option for patients with previously treated, inoperable/metastatic HR-positive/HER2-negative breast cancer.

Authors

Institutions

Publication Details

Journal
Annals of Oncology
Published
2025-12-01
DOI
https://doi.org/10.1016/j.annonc.2025.12.017
Citations
2
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
2.09
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study

P.E.Rubini Liedke, S. Khan, N.Martínez Jañez, J. Tsurutani et al.
2 citations
Annals of Oncology
HER2/EGFR in Cancer Research
2.09
article

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study

P.E.Rubini Liedke, S. Khan, N.Martínez Jañez, J. Tsurutani, B. Pistilli, M. Hattori, D. Carroll, Y.-S. Lu, S.-A. Im, K. Jhaveri, D.W. Cescon, S. G. Wang, A. Bardia, M. De Laurentiis, K. Kalinsky, E. Hamilton, S. Pernas, G. Borges, B. Xu, H.S. Rugo
article en
2 citations

Abstract

TROPION-Breast01 met its dual primary endpoint of PFS by BICR. While there was no statistically significant improvement in the dual primary endpoint of OS with Dato-DXd versus ICC, subsequent ADC treatment may have affected OS results. The totality of efficacy and safety data supports Dato-DXd as a new treatment option for patients with previously treated, inoperable/metastatic HR-positive/HER2-negative breast cancer.

Annals of Oncology
SHOWA Medical University (JP), Memorial Sloan Kettering Cancer Center (US), Emory University (US), Sun Yat-sen University (CN), University of California, San Francisco (US), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Cornell University (US), Institut Gustave Roussy (FR), Princess Margaret Cancer Centre (CA), Seoul National University Hospital (KR), Institut d'Investigació Biomédica de Bellvitge (ES), Hospital de Clínicas de Porto Alegre (BR), Sarah Cannon (US), Institut Català d'Oncologia (ES), AstraZeneca (Netherlands) (NL), USC Norris Comprehensive Cancer Center (US), Instituto Ramón y Cajal de Investigación Sanitaria (ES), National Taiwan University Hospital (TW), Aichi Cancer Center (JP), AstraZeneca (Poland) (PL), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Universidade do Vale do Itajaí (BR), Sun Yat-sen University Cancer Center (CN), AstraZeneca (Spain) (ES), UCSF Helen Diller Family Comprehensive Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 10%
HER2/EGFR in Cancer Research
2.09
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.